Rituximab for prevention and treatment of graft-versus-host disease

Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications

(2011) Joseph Pidala et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

A Novel Reduced Toxicity Preparative Regimen For Hematopoietic Cell Allografting Combining Pentostatin (Nipent®) And Targeted Doses Of Intravenous Busulfan (Busulfex®) With Or Without Rituximab (PB±R) Using CD4-Guided Immune Suppression: Preliminary Results Of An Ongoing Prospective Trial

(2010) M.A. Kharfan-Dabaja et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Rituximab Administration within 6 Months of T Cell-Depleted Allogeneic SCT is Associated with Prolonged Life-Threatening Cytopenias

(2010) Zachariah McIver et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease

(2010) S. Sarantopoulos et al.   BLOOD

Repeated course of rituximab for treatment of nephrotic syndrome in patients with chronic GVHD

(2010) S Mellon-Reppen et al.   BONE MARROW TRANSPLANTATION

Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study

(2010) S. J. Kim et al.   HAEMATOLOGICA

Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD

(2009) Suzanne van Dorp et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis

(2009) Mohamed A. Kharfan-Dabaja et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The role of B cells in the pathogenesis of graft-versus-host disease

(2009) A. Shimabukuro-Vornhagen et al.   BLOOD

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease

(2009) S. Sarantopoulos et al.   BLOOD

Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation

(2009) Voravit Ratanatharathorn et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease

(2009) Takanori Teshima et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

330: Rituximab is Feasible to Administer to Allograft Recipients with Advanced CD20+ Malignancies and does not Affect Timely Hematopoietic Engraftment

(2008) M.A. Kharfan-Dabaja et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

(2008) I. F. Khouri et al.   BLOOD

Rituximab as salvage therapy for refractory chronic GVHD

(2008) M Mohty et al.   BONE MARROW TRANSPLANTATION

B-cell involvement in chronic graft-versus-host disease

(2008) R. Kapur et al.   HAEMATOLOGICA

Treatment of Chronic Steroid-Refractory Graft-Versus-Host Disease With Low-Dose Rituximab

(2008) Malte von Bonin et al.   TRANSPLANTATION